August 2008 Oncology News International

News
Article

Cover Story

  • High cost of biologics takes a toll on hem/onc practices
  • FDA cracks down on counterfeit cancer cure products

DEPARTMENTS

Focus on Breast Cancer

  • Mastectomy rates for early breast cancer are on the upswing at one Mayo Clinic
  • Is breast MRI primed for widespread use as a high-risk screening tool?
  • Vantage Point: Risk factors will guide the imaging paradigm

Focus on Lung Cancer

  • Anti-IGF-1R antibody plus chemo active in advanced non-small-cell lung cancer

News & Analysis

  • Oncologic drug safety: Separating fact from fiction

Focus on Prostate Cancer

  • Dual antiangiogenic therapy plus chemo is active in advanced prostate cancer

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
2 experts are featured in this series.
2 experts are featured in this series.
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
4 experts in this video
Related Content
90 Contralateral Risk Reduction Mastectomy in Patients With Unilateral Breast Cancer: A Multinational and Multidisciplinary Survey—Physicians’ Perspective

90 Contralateral Risk Reduction Mastectomy in Patients With Unilateral Breast Cancer: A Multinational and Multidisciplinary Survey—Physicians’ Perspective

Atilla Soran, MD, MPH;Kazim Senol;Schlomo Schneebaum;Shigeru Imoto;Carole Mathelin;Alexander Mundinger;Meltem Selam;Vahit Ozmen
April 21st 2025
Article
Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

T-DXd With Pertuzumab Improves PFS in HER2+ Metastatic Breast Cancer

T-DXd With Pertuzumab Improves PFS in HER2+ Metastatic Breast Cancer

Tim Cortese
April 21st 2025
Article

Data from the T-DXd monotherapy arm of the phase 3 DESTINY-Breast09 trial will remain blinded until the final PFS analysis.

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Sacituzumab govitecan plus pembrolizumab showed a trend for improved overall survival vs standard of care in patients with untreated PD-L1–positive TNBC.

Sacituzumab Govitecan/Pembrolizumab Yields Significant PFS Improvement in TNBC

Roman Fabbricatore
April 21st 2025
Article

Sacituzumab govitecan plus pembrolizumab showed a trend for improved overall survival vs standard of care in patients with untreated PD-L1–positive TNBC.

3 Things You Should Know About Unresectable NSCLC

3 Things You Should Know About Unresectable NSCLC

ONCOLOGY Staff
April 21st 2025
Article

In first-line, EGFR-mutated NSCLC, targeted therapies such as osimertinib or amivantamab plus lazertinib are recommended.